| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | 8.435 | 2.183 | 4.380 | 4.367 | 4.342 |
| Total Income - EUR | - | - | - | - | - | 10.728 | 6.669 | 8.879 | 8.852 | 8.803 |
| Total Expenses - EUR | - | - | - | - | - | 7.561 | 8.058 | 5.766 | 6.126 | 6.324 |
| Gross Profit/Loss - EUR | - | - | - | - | - | 3.168 | -1.389 | 3.113 | 2.727 | 2.479 |
| Net Profit/Loss - EUR | - | - | - | - | - | 3.083 | -1.443 | 2.991 | 2.299 | 2.142 |
| Employees | - | - | - | - | - | 1 | 1 | 0 | 0 | 0 |
Check the financial reports for the company - Ocufizmed S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | 40.938 | 34.693 | 29.447 | 24.020 | 19.528 |
| Current Assets | - | - | - | - | - | 8.624 | 10.465 | 6.932 | 5.213 | 7.111 |
| Inventories | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | - | - | 0 | 1.124 | 4.048 | 3.672 | 2.927 |
| Cash | - | - | - | - | - | 8.624 | 9.340 | 2.884 | 1.541 | 4.184 |
| Shareholders Funds | - | - | - | - | - | 2.948 | 1.440 | 4.436 | 2.348 | 4.476 |
| Social Capital | - | - | - | - | - | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | - | 12.212 | 14.564 | 7.198 | 7.504 | 7.020 |
| Income in Advance | - | - | - | - | - | 34.402 | 29.154 | 24.745 | 20.185 | 15.611 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8699 - 8699" | |||||||||
| CAEN Financial Year |
8690
|
|||||||||
Comments - Ocufizmed S.r.l.